Boehringer Ingelheim Wins Interchangeable Biosimilar To Humira, Setting Benchmark For Switching Studies

 
• By Nielsen Hobbs

Cyltezo won’t be available until 2023 due to patent settlement with AbbVie. The second-ever interchangeable biosimilar approved by the US FDA also contains a first: published data from a switch trial.

sunrise over Greece
WITH AN INTERCHANGABLE DESIGNATION TO Abbvie’s HUMIRA, BOEHRINGER INGELHEIM’S CYLTEZO COULD HEARLD THE DAWN OF A NEW ERA FOR BIOSIMILARS IN THE US. • Source: Alamy

More from Approvals

More from Product Reviews